Skip to main content

Table 1 Classification of GLP-1 RAs based on different parameters [13]

From: A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Parameter Classification Compound
Classification based on duration of action Short acting (half-life < 12 h) Exenatide
Lixisenatide
Intermediate acting (half-life 12–24 h) Liraglutide
Long acting (half-life 24 h to 1 month) Exenatide LAR
Albiglutide
Semaglutide
Orally administered semaglutide
Continuous acting (half-life > 1 month) ITCA 650
Based on structure Exendin-based therapy Exenatide
Exenatide LAR
Lixisenatide
Human GLP-1-based therapy Liraglutide
Dulaglutide
Semaglutide
Orally administered semaglutide
Based on mode of delivery Subcutaneous injection Exenatide
Exenatide LAR
Albiglutide
Lixisenatide
Liraglutide
Semaglutide
Subcutaneous implant ITCA 650
Oral ingestion Orally administered semaglutide